15 completed, 4 terminated, 3 active not recruiting, 2 not yet recruiting. 28 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 15, Terminated 4, Active not recruiting 3, Not yet recruiting 2, Recruiting 2, Withdrawn 2 |
| Phase 2 | 6 | Completed 3, Withdrawn 2, Recruiting 1 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 60 | 2026-08-01 | 2026-07-23 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 117 | 2026-08-01 | 2026-07-23 |
| A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease IBI311, Placebo - Thyroid Eye Disease | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 111 | 2025-09-10 | 2025-11-17 |
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) VRDN-003, Placebo - Thyroid Eye Disease | Phase 3 | Active not recruiting | Viridian Therapeutics, Inc. | 132 | 2024-08-27 | 2026-08-18 |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) VRDN-003, Placebo - Thyroid Eye Disease | Phase 3 | Active not recruiting | Viridian Therapeutics, Inc. | 204 | 2024-08-27 | 2026-08-18 |
| A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease Teprotumumab, Placebo - Thyroid Eye Disease | Phase 3 | Active not recruiting | Amgen | 89 | 2024-07-05 | 2026-07-07 |
| A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 231 | 2024-05-23 | 2026-08-13 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 105 | 2024-03-28 | 2026-03-16 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 102 | 2024-03-27 | 2026-03-16 |
| An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 Veligrotug - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 139 | 2024-01-31 | 2026-08-14 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Hoffmann-La Roche | 127 | 2023-11-15 | 2026-08-12 |
| An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 188 | 2023-11-01 | 2026-08-13 |
| Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease, TED | Phase 3 | Completed | Hoffmann-La Roche | 131 | 2023-10-26 | 2026-07-31 |
| Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) linsitinib - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Recruiting | Sling Therapeutics, Inc. | 75 | 2023-10-11 | 2025-02-25 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease IBI311, placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 115 | 2023-02-14 | 2024-02-08 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 86 | 2023-01-05 | 2026-04-01 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 114 | 2022-11-23 | 2025-12-03 |
| A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) Veligrotug, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 113 | 2022-11-16 | 2026-08-13 |
| Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Observational cohort study, Batoclimab - Thyroid Eye Disease | Phase 3 | Terminated | Immunovant Sciences GmbH | 109 | 2022-11-06 | 2026-04-29 |
Showing 20 of 28. Sign in to see all of them.
Graves Ophthalmopathy (28) · Exophthalmos (4) · Graves Disease (4) · Autoimmune Diseases (3) · Endocrine System Diseases (2) · Eye Diseases (2) · Hashimoto Disease (2) · Orbital Diseases (2) · Thyroid Diseases (2) · Motor Activity (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (28) · Eye Diseases, Hereditary (28) · Genetic Diseases, Inborn (28) · Goiter (28) · Hyperthyroidism (28) · Immune System Diseases (28) · Endocrine System Diseases (26) · Eye Diseases (26) · Orbital Diseases (26) · Thyroid Diseases (26) · Autoimmune Diseases (25) · Exophthalmos (24) · Graves Disease (24) · Thyroiditis (2) · Thyroiditis, Autoimmune (2)
teprotumumab (3) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · satralizumab (2) · Methylprednisolone (1) · Saline Solution (1) · Selenium (1) · Sodium Chloride (1) · secukinumab (1) · tocilizumab (1)
Viridian Therapeutics, Inc. (7) · Amgen (3) · Immunovant Sciences GmbH (3) · Beijing Kanghong Biological Medicine Co., Ltd. (2) · Hoffmann-La Roche (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Iran University of Medical Sciences (2) · Sling Therapeutics, Inc. (2) · argenx (2) · Assiut University (1) · Hospital Clinico Universitario de Santiago (1) · Novartis Pharmaceuticals (1)
United States (19) · Germany (15) · Spain (14) · United Kingdom (11) · Italy (9) · Poland (9) · Australia (8) · China (7) · France (7) · Hungary (7) · Canada (4) · Japan (4) · Turkey (Türkiye) (4) · Belgium (3) · Georgia (3)
Mohsen B Kashkouli, MD (2) · Ahmed Abdelal, MD (1) · Mohamed Shehata, MD (1) · Salma Kedwany, MD (1)
PMID 41066062, PMID 27797318, PMID 31971679, PMID 33172865, PMID 33768488, PMID 41066129
2023 (4), 2017 (2)